MX2022006519A - Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo. - Google Patents

Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.

Info

Publication number
MX2022006519A
MX2022006519A MX2022006519A MX2022006519A MX2022006519A MX 2022006519 A MX2022006519 A MX 2022006519A MX 2022006519 A MX2022006519 A MX 2022006519A MX 2022006519 A MX2022006519 A MX 2022006519A MX 2022006519 A MX2022006519 A MX 2022006519A
Authority
MX
Mexico
Prior art keywords
polyethylene glycol
medicament
glycol conjugate
preparation
conjugate medicament
Prior art date
Application number
MX2022006519A
Other languages
English (en)
Inventor
Kai Wang
Qian Zhang
Xi Liu
Yue Liu
Qiang Luo
Yue Yang
Xiao Tang
Gaoquan Li
Dajun Li
Yusong Wei
Yongchen Peng
Xiangwei Yang
Xiafan Zeng
Gang Mei
Diedie Li
Chengzhi Gao
Xiaoling Ding
Jia Gao
Yuyang Yi
Yanxia Heng
Tao Tu
Liwei Liu
Mei Liu
Jie Lou
Huiyu Chen
Yuanqiang Wang
Original Assignee
Chongqing Upgra Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chongqing Upgra Biotechnology Co Ltd filed Critical Chongqing Upgra Biotechnology Co Ltd
Publication of MX2022006519A publication Critical patent/MX2022006519A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G81/00—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
    • C08G81/02—Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers at least one of the polymers being obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • C08G81/024—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G
    • C08G81/025—Block or graft polymers containing sequences of polymers of C08C or C08F and of polymers of C08G containing polyether sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/003—Dendrimers
    • C08G83/004—After treatment of dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyamides (AREA)

Abstract

La presente invención se refiere a un medicamento conjugado con polietilenglicol, a un método de preparación del mismo y al uso del mismo y, en particular, se refiere a un medicamento conjugado con polietilenglicol representado por la fórmula (I) o una sal farmacéuticamente aceptable del mismo. La presente invención también se refiere a un método para preparar el medicamento conjugado con polietilenglicol o una sal farmacéuticamente aceptable del mismo, y a un intermedio del mismo, a una composición farmacéutica que comprende el medicamento conjugado con polietilenglicol o una sal farmacéuticamente aceptable del mismo, y al uso del mismo en la preparación de un medicamento. (ver Fórmula).
MX2022006519A 2019-11-28 2020-11-18 Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo. MX2022006519A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201911190064 2019-11-28
CN202010738638 2020-07-28
CN202010737415 2020-07-28
PCT/CN2020/129705 WO2021104120A1 (zh) 2019-11-28 2020-11-18 一种聚乙二醇偶联药物、其制备方法及用途

Publications (1)

Publication Number Publication Date
MX2022006519A true MX2022006519A (es) 2022-08-19

Family

ID=75996355

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006519A MX2022006519A (es) 2019-11-28 2020-11-18 Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.

Country Status (10)

Country Link
US (1) US11793881B2 (es)
EP (1) EP4066861A4 (es)
JP (1) JP2022554026A (es)
KR (1) KR102542715B1 (es)
CN (1) CN112851928B (es)
AU (1) AU2020389657A1 (es)
BR (1) BR112022010360A2 (es)
CA (1) CA3159842A1 (es)
MX (1) MX2022006519A (es)
WO (1) WO2021104120A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3189933A1 (en) * 2020-07-28 2022-02-03 Chongqing Upgra Biotechnology Co., Ltd. Polyethylene glycol conjugate drug, and preparation method therefor and use thereof
WO2022022354A1 (zh) * 2020-07-28 2022-02-03 重庆阿普格雷生物科技有限公司 聚乙二醇偶联药物增效剂、其制备方法及用途
WO2022242488A1 (zh) * 2021-05-18 2022-11-24 重庆阿普格雷生物科技有限公司 聚乙二醇偶联药物及其用途
CN116354976A (zh) * 2021-12-27 2023-06-30 上海复旦张江生物医药股份有限公司 喜树碱衍生物的纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214966B1 (en) * 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20050158273A1 (en) * 1997-09-25 2005-07-21 Harris J. M. Soluble, degradable polyethylene glycol) derivatives for controllable release of bound molecules into solution
WO2013096388A1 (en) * 2011-12-21 2013-06-27 The Regents Of The University Of California Telodendrimers with enhanced drug delivery
US11406714B2 (en) * 2013-08-21 2022-08-09 The Research Foundation For The State University Of New York Telodendrimers and nanocarriers and methods of using same
CN104877127B (zh) * 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
CN104758946B (zh) * 2015-04-07 2017-09-29 中国科学院过程工程研究所 一种抗体偶联药物及其制备方法和应用
CN104987504B (zh) * 2015-04-23 2018-05-01 南京明臻医药科技有限公司 聚乙二醇化拉帕替尼及其注射剂和制备方法
CN105601903B (zh) 2015-12-25 2017-10-24 大连理工大学 一种具有抗癌活性的高分子化合物、其制备方法和应用
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
CN107670048B (zh) * 2017-08-30 2019-04-26 南京明臻医药科技有限公司 具有协同抗癌活性的中间体药物和聚乙二醇偶联协同抗癌药物、及其制备方法和应用
CN107670050B (zh) * 2017-08-30 2019-06-07 重庆阿普格雷生物科技有限公司 基于pki-587的抗癌中间体和聚乙二醇偶联抗癌药物、及其制备方法和应用
CN111514309B (zh) * 2019-02-03 2021-09-17 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及用途
CN112843242B (zh) * 2019-11-28 2024-03-01 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及应用
CN112915210A (zh) * 2019-12-06 2021-06-08 重庆阿普格雷生物科技有限公司 一种聚乙二醇偶联药物、其制备方法及应用

Also Published As

Publication number Publication date
BR112022010360A2 (pt) 2022-08-16
US20230088403A1 (en) 2023-03-23
WO2021104120A1 (zh) 2021-06-03
EP4066861A1 (en) 2022-10-05
US11793881B2 (en) 2023-10-24
KR20220102659A (ko) 2022-07-20
CN112851928B (zh) 2023-04-25
CA3159842A1 (en) 2021-06-03
CN112851928A (zh) 2021-05-28
JP2022554026A (ja) 2022-12-27
AU2020389657A1 (en) 2022-06-23
KR102542715B1 (ko) 2023-06-14
EP4066861A4 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
MX2022006519A (es) Medicamento conjugado con polietilenglicol, metodo de preparacion del mismo y uso del mismo.
MX2017012393A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
GEP201606555B (en) Compounds and compositions for modulating egfr activity
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2021006969A (es) Ligante peptidico.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021012708A (es) Formulaciones novedosas que comprenden melflufen.
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
MX2021015543A (es) Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo.
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
MX2021014680A (es) Derivado de benzotriazol.
PH12021551057A1 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2021003739A (es) Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos.
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
PH12021550439A1 (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CA3155875A1 (en) BIARYL COMPOUND SUBSTITUTED BY SULFO OR CORRESPONDING SALT, METHOD FOR PREPARATION AND USE
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
MX2021015727A (es) Derivados de piridin-3-ilo.
MX2022006489A (es) Derivado de anillo de piridina fusionado, metodo de preparacion y usos farmaceuticos del mismo.